º´¸®ÇÐÀû º´±â Ia±â ºñ¼Ò¼¼Æ÷Æó¾Ï ȯÀÚ¿¡¼­ ¿ÏÀüÀýÁ¦¼ú ÈÄ »ç¸ÁÀÇ ¿øÀο¡ µû¸¥ À§ÇèÀÎÀÚ ºÐ¼®
Cause-specific Analysis of Risk Factors in Completely Resected Pathologic Stage Ia Non-small Cell Lung Cancer

´ëÇÑÈäºÎ¿Ü°úÇÐȸÁö 2009³â 42±Ç 6È£ p.725 ~ p.731

¹Ú¼º¿ë(Park Seong-Yong) - ±¹¸³¾Ï¼¾ÅÍ Æó¾Ï¼¾ÅÍ ÈäºÎ¿Ü°ú
¹ÚÀαÔ(Park In-kyu) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ÈäºÎ¿Ü°úÇб³½Ç
º¯Ãµ¼º(Byeon Cheun-Sung) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ÈäºÎ¿Ü°úÇб³½Ç
ÀÌ⿵(Lee Chang-Young) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ÈäºÎ¿Ü°úÇб³½Ç
¹è¹Ì°æ(Bae Mi-Kyung) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ÈäºÎ¿Ü°úÇб³½Ç
±è´ëÁØ(Kim Dae-Joon) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ÈäºÎ¿Ü°úÇб³½Ç
Á¤°æ¿µ(Chung Kyung-Young) - ¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ÈäºÎ¿Ü°úÇб³½Ç

Abstract

¹è°æ: Ia º´±âÀÇ ºñ¼Ò¼¼Æ÷¼ºÆó¾Ï¿¡¼­ Æó¿± ÀýÁ¦¼ú°ú Á¾°Ýµ¿ ¸²ÇÁÀý û¼Ò¼úÀº Ç¥ÁØ Ä¡·á·Î ¹Þ¾Æµé¿©Áö°í ÀÖÀ¸³ª ¾à 15¡­40%ÀÇ È¯ÀÚÀÇ Àç¹ß ¶Ç´Â »ç¸Á µîÀÇ Ä¡·á ½ÇÆи¦ °æÇèÇÏ°Ô µÈ´Ù. ÀúÀÚµéÀº Ia ºñ¼ÒÆ÷¼ºÆó¾Ï¿¡¼­ÀÇ Ä¡·á ½ÇÆÐ À¯ÇüÀ» ºÐ¼®ÇÏ°í °¢°¢¿¡ µû¸¥ À§Çè ÀÎÀÚ¸¦ ºÐ¼®ÇÏ°íÀÚ ÇÏ¿´´Ù.

´ë»ó ¹× ¹æ¹ý: 1992³â 1¿ùºÎÅÍ 2005³â 8¿ù±îÁö ºñ¼Ò¼¼Æ÷¼ºÆó¾ÏÀ¸·Î ¿ÏÀü(R0)ÀýÁ¦¼úÀ» ½ÃÇà¹ÞÀº 156¸íÀÇ È¯ÀÚ¸¦ ´ë»óÀ¸·Î ÈÄÇâÀûÀÎ ¿¬±¸¸¦ ½ÃÇàÇÏ¿´´Ù. Ä¡·á ½ÇÆÐÀÇ ¿øÀÎÀ» Æó¾Ï¿¬°ü »ç¸Á ¹× Æó¾Ï¹«°ü »ç¸ÁÀ¸·Î ºÐ·ùÇÏ°í °¢°¢ÀÇ À§ÇèÀÎÀÚ¸¦ ºÐ¼®ÇÏ¿´´Ù.

°á°ú: Àüü 156¸íÀÇ È¯ÀÚÁß ³²ÀÚ°¡ 93¸í, ¿©ÀÚ´Â 63¸íÀ̾úÀ¸¸ç, Æò±Õ ¿¬·ÉÀº 61.31¼¼¿´´Ù. Áß¾Ó ÃßÀû°üÂû ±â°£Àº 33.8°³¿ùÀ̾ú´Ù. 5³â »ýÁ¸À²Àº 87.6%¿´°í 10³â »ýÁ¸À²Àº 78.3%¿´´Ù. ¹Ì¼¼ ¸²ÇÁ°ü-Ç÷°ü ħÀ±ÀÌ ÀÖ¾ú´ø ȯÀÚ´Â 10¸íÀ̾ú´Ù. ÃßÀû±â°£ Áß 19¿¹ÀÇ Æó¾ÏÀç¹ßÀÌ Áø´ÜµÇ¾úÀ¸¸ç, 12¿¹ÀÇ Æó¾Ï¿¬°ü »ç¸ÁÀÌ ¹ß»ýÇÏ¿´´Ù. Æó¾Ï¹«°ü »ç¸ÁÀº 16¿¹¿¡¼­ ¹ß»ýÇÏ¿´´Ù.Æó¾Ï Àç¹ß°ú Æó¾Ï¿¬°ü »ç¸ÁÀÇ À§ÇèÀÎÀÚ´Â ¹Ì¼¼ ¸²ÇÁ°ü-Ç÷°ü ħÀ±(HR=6.81, p=0.007, HR=7.81, p£¼0.001)À̾úÀ¸¸ç, Æó¾Ï¹«°ü À§ÇèÀÎÀÚ´Â ÀüÆóÀýÁ¦¼ú(HR=25.92, p=0.001)°ú ¼ö¼ú ÈÄ ½ÉÇ÷°ü°è ¶Ç´Â È£Èí±â°èÅëÀÇ ÇÕº´Áõ ¹ß»ý¿©ºÎ(HR=29.67, p=0.002)ÀÎ °ÍÀ¸·Î ³ªÅ¸³µ´Ù.

°á·Ð: Ia ºñ¼Ò¼¼Æ÷¼ºÆó¾ÏÀÇ ¿ÏÀüÀýÁ¦¼ú ÈÄ »ç¸Á ¿øÀÎÀº Àç¹ß°ú ÀÌ·Î ÀÎÇÑ Æó¾Ï¿¬°ü »ç¸Á»Ó¸¸ ¾Æ´Ï¶ó Æó¾Ï¹«°ü »ç¸Á ¶ÇÇÑ ¸¹Àº ºñÀ²À» Â÷ÁöÇÑ´Ù. Àç¹ß ¹× Æó¾Ï¿¬°ü »ç¸ÁÀÇ À§ÇèÀÎÀÚÀÎ ¹Ì¼¼ ¸²ÇÁ°ü-Ç÷°ü ħÀ±ÀÌ Àִ ȯÀÚµé ´ë»óÀ¸·Î ¼ö¼ú ÈÄ º¸Á¶ Ç׾Ͽä¹ýÀ» ¼±ÅÃÀûÀ¸·Î ½ÃÇàÇÏ´Â °ÍÀÌ µµ¿òÀÌ µÉ ¼ö ÀÖÀ» °ÍÀ¸·Î ÆǴܵǸç, ÀüÆóÀýÁ¦¼úÀ» ¹ÞÀº ȯÀÚ³ª ½ÉÇ÷°ü°è ¶Ç´Â È£Èí±â°è ÇÕº´ÁõÀÌ ¹ß»ýÇß´ø ȯÀڵ鿡 À־´Â º´¹ßÁõÀ¸·Î ÀÎÇÑ »ç¸ÁÀ» ÁÙÀ̱â À§ÇØ ¼¼½ÉÇÑ °ü¸®°¡ ÇÊ¿äÇÒ °ÍÀ¸·Î ÆǴܵȴÙ.
Background: Lobectomy and more extended anatomic resection are regarded as standard treatment for stage Ia non-small cell lung cancer, but approximately 15¡­40% of patients suffer from treatment failures such as cancer recurrence or death. The authors analyzed types and causes of treatment failures in surgically treated cases of stage Ia non small cell lung cancer.

Material and Method: We retrospectively reviewed the medical records of 156 patients who had undergone complete resection for stage Ia NSCLC between Jan 1992 and Aug 2005. Patients were divided into two different treatment failure groups: cancer-related deaths and non-cancer-related deaths. Risk factors were analyzed in each group by the Kaplan-Meyer survival method and the Cox proportional hazard model.

Result: Among the 156 patients, 93 were males; the mean age was 61. The median follow-up period was 33.8 months. The 5 year survival rate was 87.6%. Microscopic lympho-vascular permeation was reported in 10 patients. Recurrence was reported in 19 patients and 12 patients died due to recurrent lung cancer. Non- cancer related deaths occurred in 16 patients. Risk factors for cancer recurrence and cancer related death were microscopic lympho-vascular permeation (HR=6.81, p=0.007, HR=7.81, p£¼0.001); for non-cancer related death, risk factors were pneumonectomy (HR=25.92, p=0.001) and postoperative cardiopulmonary complications (HR=29.67, p=0.002).

Conclusion: After complete resection of stage Ia non small cell lung cancer patients, mortality includes not only cancer related deaths but also cancer unrelated deaths. Adjuvant chemotherapy is advised for patients who show microscopic lympho-vascular permeation, which is a risk factor for recurrence and for cancer related death. Patients who had pneumonectomy or who suffered from cardiac or respiratory complications need meticulous care in order to reduce comorbidity-induced death.

Å°¿öµå

Æó¾ÏÁ¾, ¼ö¼úÈÄ °ü¸®, ¾ÏÁ¾ Àç¹ß
Lung neoplasm, Postoperative care, Neoplasm recurrence
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
Adjuvant chemotherapy is advised for patients who show microscopic lympho-vascular permeation, which is a risk factor for recurrence and for cancer related death
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå